Mood-Stabilizing Agents

  • Ross J. Baldessarini


Mood-stabilizing treatments include a variety of types of medicinal agents with important applications in the treatment of bipolar (manic-depressive) disorder patients. Recent estimates indicate that the prevalence of these illnesses exceeds that of the psychotic disorders, with lifetime estimates ranging from approximately 1% for type I bipolar disorder (with mania) to several percent if all forms of bipolar disorder (including type II with hypomania and mainly recurrent depression).


Bipolar Disorder Mixed State Bipolar Depression Acute Mania Lithium Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Adams F, editor. The Extant Works of Aretaeus, the Cappadocian. Boston: Milford House; 1972/1856.Google Scholar
  2. 2.
    Adzick NS, Thom EA, Spong CY, Brock III JW, Burrows PK, Johnson MP, et al. Randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med. 2011;364:993–1004.PubMedGoogle Scholar
  3. 3.
    Ahrens B, Müller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry. 2001;34:132–6.PubMedGoogle Scholar
  4. 4.
    Akiskal HS. Mood disorders: historical introduction and conceptual overview, Chap. 13.1. In: Sadock BJ, Sadock VA, editors. Mood Disorders, Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, vol. 1. 9th ed. Philadelphia: Wolters Kluver/Lippincott Williams & Wilkins; 2009. p. 1629–45.Google Scholar
  5. 5.
    Akiskal HS, Benazzi F. DSM-IV and ICD-10 categories of recurrent [major] depressive and bipolar II disorders: evidence that they lie on a dimensional spectrum. J Affect Disord. 2006;92:45–54.PubMedGoogle Scholar
  6. 6.
    Aliasgharpour M, Hagani H. Evaluation of lithium determination in three analyzers: flame emission, flame atomic absorption spectroscopy and ion selective electrode. N Am J Med Sci. 2009;1:244–6.PubMedGoogle Scholar
  7. 7.
    Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry. 1995;152:1130–8.PubMedGoogle Scholar
  8. 8.
    Altamura AC, Lietti L, Dobrea C, Benatti B, Arici C, Dell’Osso B. Mood stabilizers for patients with bipolar disorder: state of the art. Expert Rev Neurother. 2011;11:85–99.PubMedGoogle Scholar
  9. 9.
    Amann B, Born C, Crespo JM, Pomarol-Clotet E, McKenna P. Lamotrigine: when and where does it act in affective disorders? systematic review. J Psychopharmacol. 2011;25:1289–94.PubMedGoogle Scholar
  10. 10.
    Amdisen A. Clinical features and management of lithium poisoning. Med Toxicol Adverse Drug Exp. 1988;3:18–32.PubMedGoogle Scholar
  11. 11.
    American Psychiatric Association (APA). Diagnostic and Statistical Manual, third and fourth revisions (DSM-III, -IV, and IV-text-revision). Washington, DC: American Psychiatric Press; 1980, 1994, 2000.Google Scholar
  12. 12.
    Amsterdam JD, Shults J. Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. J Clin Psychopharmacol. 2010;30:306–11.PubMedGoogle Scholar
  13. 13.
    Amsterdam JD, Wang G, Shults J. Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapy. Acta Psychiatr Scand. 2010;121:201–8.PubMedGoogle Scholar
  14. 14.
    Angst J, Angst F, Gerber-Werder R, Gamma A. Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years’ follow-up. Arch Suicide Res. 2005;9: 279–300.PubMedGoogle Scholar
  15. 15.
    Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord. 2002;68:167–81.PubMedGoogle Scholar
  16. 16.
    Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med. 2010;363:542–51.PubMedGoogle Scholar
  17. 17.
    Ardinger HH, Atkin JF, Blackston RD, Elsas LJ, Clarren SK, Livingstone S, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet. 1988;29:171–85.PubMedGoogle Scholar
  18. 18.
    Baethge C, Baldessarini RJ, Bratti IM, Tondo L. Prophylaxis-latency and outcome in bipolar disorders. Can J Psychiatry. 2003;48:449–57.PubMedGoogle Scholar
  19. 19.
    Baethge C, Baldessarini RJ, Khalsa HMK, Hennen J, Salvatore P, Tohen M. Substance abuse in first-episode bipolar I disorder: indications for early intervention. Am J Psychiatry. 2005;162:1008–10.PubMedGoogle Scholar
  20. 20.
    Baethge C, Baldessarini RJ, Mathiske-Schmidt K, Hennen J, Berghofer A, Muller-Oerlinghausen B, et al. Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. J Clin Psychiatry. 2005;66:174–82.PubMedGoogle Scholar
  21. 21.
    Baethge C, Salvatore P, Baldessarini RJ. On cyclic insanity (1882) by Karl Ludwig Kahlbaum, MD: translation and commentary. Harv Rev Psychiatry. 2003;11:78–90.PubMedGoogle Scholar
  22. 22.
    Bagary M. Epilepsy, antiepileptic drugs and suicidality. Curr Opin Neurol. 2011;24:177–82.PubMedGoogle Scholar
  23. 23.
    Baldessarini RJ. Plea for integrity of the bipolar disorder concept. Bipolar Disord. 2000;2:3–7.PubMedGoogle Scholar
  24. 24.
    Baldessarini RJ. Commentary: the bipolar affective disorder: lithium/anticonvulsant evaluation (BALANCE) study. Bipolar Disord. 2010;12:669–72.PubMedGoogle Scholar
  25. 25.
    Baldessarini RJ, Henk HJ, Sklar AR, Chang J, Leahy LF. Psychotropic medications for bipolar disorder patients in the United States: polytherapy and adherence. Psychiatr Serv. 2008;59:1175–83.PubMedGoogle Scholar
  26. 26.
    Baldessarini RJ, Kopin IJ. Effect of drugs on release of [3H]-norepinephrine from central nervous system tissues by electrical stimulation in vitro. J Pharmacol Exp Ther. 1967;156:31–8.PubMedGoogle Scholar
  27. 27.
    Baldessarini RJ, Leahy LF, Arcona S, Gause D, Zhang W, Hennen J. Prescribing patterns of psychotropic medicines in the United States for patients diagnosed with bipolar disorders. Psychiatr Serv. 2007;58:85–91.PubMedGoogle Scholar
  28. 28.
    Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum Psychopharmacol. 2008;23:95–105.PubMedGoogle Scholar
  29. 29.
    Baldessarini RJ, Salvatore P, Khalsa H-MK, Gebre-Medhin P, Imaz H, González-Pinto A, et al. Morbidity in 303 first-episode bipolar I disorder patients. Bipolar Disord. 2010;12:264–70.PubMedGoogle Scholar
  30. 30.
    Baldessarini RJ, Salvatore P, Khalsa H-MK, Imaz-Etxeberria H, Gonzalez-Pinto A, Tohen M. Episode cycles with increasing recurrences in first-episode bipolar-I disorder patients. J Affect Disord. 2011;136:149–54.PubMedGoogle Scholar
  31. 31.
    Baldessarini RJ, Salvatore P, Khalsa H-MK, Tohen M. Dissimilar morbidity following initial mania vs. mixed-states in type-I bipolar disorder. J Affect Disord. 2010;126:299–302.PubMedGoogle Scholar
  32. 32.
    Baldessarini RJ, Stephens J. Lithium carbonate for affective disorder: clinical pharmacology and toxicology. Arch Gen Psychiatry. 1970;22:72–77.PubMedGoogle Scholar
  33. 33.
    Baldessarini RJ, Suppes T, Tondo L. Lithium withdrawal in bipolar disorder: implications for clinical practice and experimental therapeutics research. Am J Ther. 1996;3:492–6.PubMedGoogle Scholar
  34. 34.
    Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. Chap. 18. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman’s Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill; 2005. p. 461–500.Google Scholar
  35. 35.
    Baldessarini RJ, Tondo L. Antisuicide effects of lithium and anticonvulsants: update. Bipolar Disord. 2008;10:114–5.PubMedGoogle Scholar
  36. 36.
    Baldessarini RJ, Tondo L. Meta-analytic comparison of antisuicidal effects of lithium versus anticonvulsants. Pharmacopsychiatry. 2009;42:72–5.PubMedGoogle Scholar
  37. 37.
    Baldessarini RJ, Tondo L, Baethge C, Lepri B, Bratti IM. Effects of treatment-latency on response to maintenance treatment in manic-depressive disorders. Bipolar Disord. 2007;9:386–93.PubMedGoogle Scholar
  38. 38.
    Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: meta-analytic review. Bipolar Disord. 2006;8:625–39.PubMedGoogle Scholar
  39. 39.
    Baldessarini RJ, Tondo L, Faedda GL, Viguera AC, Baethge C, Salvatore P, et al. Latency, discontinuation, and re-use of lithium treatment. In: Bauer M, Grof P, Müller-Oerlinghausen B, editors. Lithium in neuropsychiatry: the comprehensive guide. London: Taylor & Francis; 2007. p. 465–81.Google Scholar
  40. 40.
    Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry. 2010;167:934–41.PubMedGoogle Scholar
  41. 41.
    Baldessarini RJ, Tondo L, Hennen J. Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients. J Affect Disord. 2000;61:13–22.PubMedGoogle Scholar
  42. 42.
    Baldessarini RJ, Tondo L, Hennen J. Latency and episodes before treatment: effects on pretreatment morbidity but not response to maintenance treatment in bipolar I and II disorders. Bipolar Disord. 2003;5:169–79.PubMedGoogle Scholar
  43. 43.
    Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry. 2003;64 (Suppl 5):44–52.PubMedGoogle Scholar
  44. 44.
    Baldessarini RJ, Tondo L, Hennen J, Viguera AC. Is lithium still worth using? An update of selected recent research. Harv Rev Psychiatry. 2002;10:59–75.PubMedGoogle Scholar
  45. 45.
    Baldessarini RJ, Tondo L, Lepri B. Empirical test of a basic assumption underlying survival analysis as applied to experimental therapeutics in psychopharmacology. J Clin Psychopharmacol. 2010;30:72–5.PubMedGoogle Scholar
  46. 46.
    Baldessarini RJ, Undurraga J, Vázquez GH, Tondo L, Salvatore P, Ha K, et al. Predominant recurrence polarity among 928 adult international bipolar-I disorder patients. Acta Psychiatr Scand. 2012;125:293–302.PubMedGoogle Scholar
  47. 47.
    Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden C. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010;18:143–57.PubMedGoogle Scholar
  48. 48.
    Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry. 1980;137:782–90.PubMedGoogle Scholar
  49. 49.
    Bauer M, Adli M, Bschor T, Pilhatsch M, Pfennig A, Sasse J, et al. Lithium’s emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. Neuropsychobiology. 2010;62:36–42.PubMedGoogle Scholar
  50. 50.
    Bauer M, Döpfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol. 1999;19:427–34.PubMedGoogle Scholar
  51. 51.
    Bauer M, Grof P, Müller-Oerlinghausen B, editors. Lithium in neuropsychiatry: the comprehensive guide. London: Taylor & Francis; 2007.Google Scholar
  52. 52.
    Beatriz S, Fagundes R. Valproic acid: review. Rev Neurosci. 2008;16:130–6.Google Scholar
  53. 53.
    Beaulieu JM, Caron MG. Looking at lithium: molecular moods and complex behavior. Mol Interv. 2008;8:230–41.PubMedGoogle Scholar
  54. 54.
    Bedford JJ, Weggery S, Ellis G, McDonald FJ, Joyce PR, Leader JP, et al. Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride. Clin J Am Soc Nephrol. 2008;3: 1324–31.PubMedGoogle Scholar
  55. 55.
    Bellivier F, Yon L, Luquiens A, Azorin JM, Bertsch J, Gerard S, et al. Suicidal attempts in bipolar disorder: results from an observational study (EMBLEM). Bipolar Disord. 2011;13:377–86.PubMedGoogle Scholar
  56. 56.
    Bendz H, Schön S, Attman PO, Aurell M. Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int. 2010;77:219–24.PubMedGoogle Scholar
  57. 57.
    Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes JR. Pharmacological interventions for the prevention of relapse in bipolar disorder: systematic review of controlled trials. J Psychopharmacol. 2009;23:574–91.PubMedGoogle Scholar
  58. 58.
    Bhuvaneswar C, Alpert J, Harsh V, Baldessarini RJ. Adverse endocrine and metabolic effects of psychotropic drugs. CNS Drugs. 2009;23:1003–21.PubMedGoogle Scholar
  59. 59.
    Biel MG, Peselow E, Mulcare L, Case BG, Fieve R. Continuation versus discontinuation of lithium in recurrent bipolar illness: a naturalistic study. Bipolar Disord. 2007;9:435–42.PubMedGoogle Scholar
  60. 60.
    Bond DJ, Lam RW, Yatham LN. Divalproex sodium vs. placebo in the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord. 2010;124:228–34.PubMedGoogle Scholar
  61. 61.
    Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG Jr, Chou JC, Keck PE Jr, Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ. Randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry. 2000;57:481–9.PubMedGoogle Scholar
  62. 62.
    Bowen RC, Grof P, Grof E. Less frequent lithium administration and lower urine volume. Am J Psychiatry. 1991;148:189–92.PubMedGoogle Scholar
  63. 63.
    Bratti IM, Baldessarini RJ, Baethge C, Tondo L. Pretreatment episode count and response to lithium treatment in manic-depressive illness. Harv Rev Psychiatry. 2003;11:245–56.PubMedGoogle Scholar
  64. 64.
    Brennan PA, Pargas R, Walker EF, Green P, Newport DJ, Stowe Z. Maternal depression and infant cortisol: influences of timing, comorbidity and treatment. J Child Psychol Psychiatry. 2008;49:1099–107.PubMedGoogle Scholar
  65. 65.
    Brown E, Dunner DL, McElroy SL, Keck PE, Adams DH, Degenhardt E, et al. Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol. 2009;12:773–82.PubMedGoogle Scholar
  66. 66.
    Brown EB, McElroy SL, Keck Jr PE, Deldar A, Adams DH, Tohen M, et al. Seven-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006;67:1025–33.PubMedGoogle Scholar
  67. 67.
    Brunello N, Tascedda F. Cellular mechanisms and second messengers: relevance to the psychopharmacology of bipolar disorders. Int J Neuropsychopharmacol. 2003;6:181–9.PubMedGoogle Scholar
  68. 68.
    Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2:349–52.PubMedGoogle Scholar
  69. 69.
    Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord. 2008;10:323–33.PubMedGoogle Scholar
  70. 70.
    Calabrese JR, Ketter TA, Youakim JM, Tiller JM, Yang R, Frye MA. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2010;71: 1363–70.PubMedGoogle Scholar
  71. 71.
    Calabrese JR, Shelton MD, Rapport DJ, Kujawa M, Kimmel SE, Caban S. Current research on rapid cycling bipolar disorder and its treatment. J Affect Disord. 2001;67:241–55.PubMedGoogle Scholar
  72. 72.
    Calderó J, Brunet N, Tarabal O, Piedrafita L, Hereu M, Ayala V, et al. Lithium prevents excitotoxic cell death of motoneurons in organotypic slice culture of spinal cord. Neuroscience. 2010;165:1353–69.PubMedGoogle Scholar
  73. 73.
    Carey TS, Williams Jr JW, Oldham JM, Goodman F, Ranney LM, Whitener L, et al. Gabapentin in the treatment of mental illness: the echo chamber of the case series. J Psychiatr Pract. 2008;14 (Suppl 1):15–27.PubMedGoogle Scholar
  74. 74.
    Centorrino F, Albert MJ, Berry JM, Kelleher JP, Fellman V, Line G, et al. Oxcarbazepine: clinical experience with hospitalized psychiatric patients. Bipolar Disord. 2003;5:370–4.PubMedGoogle Scholar
  75. 75.
    Centorrino F, Ventriglio A, Vincenti A, Talamo A, Baldessarini RJ. Changes in medication practices for hospitalized psychiatric patients: 2009 vs. 2004. Hum Psychopharmacol. 2010;25:179–86.PubMedGoogle Scholar
  76. 76.
    Chaudron LH, Jefferson JW. Mood stabilizers during breastfeeding: review. J Clin Psychiatry. 2000;61:79–90.PubMedGoogle Scholar
  77. 77.
    Chen G, Henter ID, Manji HK. Translational research in bipolar disorder: emerging insights from genetically based models. Mol Psychiatry. 2010;15:883–95.PubMedGoogle Scholar
  78. 78.
    Chiu CT, Liu G, Leeds P, Chuang DM. Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington’s disease. Neuropsychopharmacology. 2011;36:2406–21.PubMedGoogle Scholar
  79. 79.
    Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: multiple-treatments meta-analysis. Lancet. 2011;378:1306–15.PubMedGoogle Scholar
  80. 80.
    Cipriani A, Smith K, Burgess S, Carney S, Goodwin G, Geddes J. Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. Cochrane Database Syst Rev. 2006;4:CD003492.Google Scholar
  81. 81.
    Ceron-Litvoc D, Soares BG, Geddes J, Litvoc J, de Lima MS. Comparison of carbamazepine and lithium in treatment of bipolar disorder: systematic review of randomized controlled trials. Hum Psychopharmacol. 2009;24:19–28.PubMedGoogle Scholar
  82. 82.
    Choe HK, Son GH, Chung S, Kim M, Sun W, Kim H, et al. Maternal stress retards fetal development in mice with transcriptome-wide impact on gene expression profiles of the limb. Stress. 2011;14:194–204.PubMedGoogle Scholar
  83. 83.
    Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. Reevaluation of risk of in utero exposure to lithium. JAMA. 1994;271:146–50.PubMedGoogle Scholar
  84. 84.
    Cohen LS, Wang B, Nonacs R, Viguera AC, Lemon EL, Freeman MP. Treatment of mood disorders during pregnancy and postpartum. Psychiatr Clin North Am. 2010;33:273–93.PubMedGoogle Scholar
  85. 85.
    Colom F, Vieta E, Duban C, Pacchiarrotti I, Sanchez-Moreno J. Clinical and therapeutic implications of predominant polarity in bipolar disorder. J Affect Disord. 2006;93:13–7.PubMedGoogle Scholar
  86. 86.
    Cox DR, Oakes D. Analysis of Survival Data. London: Chapman & Hall; 2001.Google Scholar
  87. 87.
    Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007;68:935–40.PubMedGoogle Scholar
  88. 88.
    Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valenti M, Vieta E. Antipsychotic drugs in acute bipolar depression. Int J Neuropharmacol. 2010;13:5–14.Google Scholar
  89. 89.
    Cuffí ML, Artells R, Navarro A, Ciruela F, Carbonell L. Regulation of α-adrenoceptor gene expression by chronic lithium treatment in rat brain. Methods Find Exp Clin Pharmacol. 2010;2010:721–5.Google Scholar
  90. 90.
    Curia G, Aracri P, Sancini G, Mantegazza M, Avanzini G, Franceschetti S. Protein-kinase C-dependent phosphorylation inhibits the effect of the antiepileptic drug topiramate on the persistent fraction of sodium currents. Neuroscience. 2004;127:63–8.PubMedGoogle Scholar
  91. 91.
    Dave M, Langbart MM. Nadolol for lithium tremor in the presence of liver damage. Ann Clin Psychiatry. 1994;6:51–2.PubMedGoogle Scholar
  92. 92.
    Dayer A, Aubry JM, Roth L, Ducrey S, Bertschy G. A theoretical reappraisal of mixed states: dysphoria as a third dimension. Bipolar Disord. 2000;2:316–24.PubMedGoogle Scholar
  93. 93.
    Deb AA, Wilson SS, Rove KO, Kumar B, Koul S, Lim DD, et al. Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro. J Urol. 2011;186:2426–33.PubMedGoogle Scholar
  94. 94.
    De Fruyt J, Deschepper E, Audenaert K, Constant E, Floris M, Pitchot W, et al. Second-generation antipsychotics in the treatment of bipolar depression: systematic review and meta-analysis. J Psychopharmacol. 2011 [Epub ahead of print, 22 Sept].Google Scholar
  95. 95.
    Denicoff KD, Meglathery SB, Post RM, Tandeciarz SI. Efficacy of carbamazepine compared with other agents: a clinical practice survey. J Clin Psychiatry. 1994;55:70–6.PubMedGoogle Scholar
  96. 96.
    Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry. 1997;58:470–8.PubMedGoogle Scholar
  97. 97.
    Dennison U, Clarkson M, O’Mullane J, Cassidy EM. Incidence and clinical correlates of lithium toxicity: retrospective review. Ir J Med Sci. 2011;180:661–75.PubMedGoogle Scholar
  98. 98.
    Devaki R, Shankar Rao S, Nadgir SM. Effect of lithium on the adrenoceptor-mediated second messenger system in rat brain. J Psychiatry Neurosci. 2006;31:246–52.PubMedGoogle Scholar
  99. 99.
    Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. Randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67:793–802.PubMedGoogle Scholar
  100. 100.
    Dou G, Aleshin O, Datta A, Yuan C. Automated enzymatic assay for measurement of lithium ions in human serum. Clin Chem. 2005;51:1989–91.PubMedGoogle Scholar
  101. 101.
    Dubé S, Tollefson GD, Thase ME, Briggs SD, Van Campen LE, Case M, et al. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord. 2007;9:618–27.PubMedGoogle Scholar
  102. 102.
    Dumlu K, Orhon Z, Özerdem A, Tural Ü, Ulas H, Tunca Z. Treatment-induced manic switch in the course of unipolar depression can predict bipolarity: cluster-analysis based evidence. J Affect Disord. 2011;134:91–101.PubMedGoogle Scholar
  103. 103.
    Duncan RE, Bazinet RP. Brain arachidonic acid uptake and turnover: implications for signaling and bipolar disorder. Curr Opin Clin Nutr Metab Care. 2010;13:130–8.PubMedGoogle Scholar
  104. 104.
    Einarson A. Safety of psychotropic drug use during pregnancy: review. MedGenMed. 2005;7:3–12.
  105. 105.
    El-Mallakh RS, Salem MR, Chopra A, Mickus GJ, Penagaluri P, Movva R. Blinded, randomized comparison of immediate-release and extended-release carbamazepine capsules in manic and depressed bipolar subjects. Ann Clin Psychiatry. 2010;22:3–8.PubMedGoogle Scholar
  106. 106.
    Emrich HM, von Zerssen D, Kissling W, Möller HJ, Windorfer A. Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch Psychiatr Nervenkr. 1980;229:1–16.PubMedGoogle Scholar
  107. 107.
    Faedda GL, Baldessarini RJ, Suppes T, Tondo L, Becker I, Lipschitz D. Pediatric-onset bipolar disorder: a neglected clinical and public health problem. Harv Rev Psychiatry. 1995;3:171–95.PubMedGoogle Scholar
  108. 108.
    Faedda GL, Baldessarini RJ, Tohen M, Strakowski SM, Waternaux C. Episode sequence in bipolar disorder and response to lithium treatment. Am J Psychiatry. 1991;148:1237–9.PubMedGoogle Scholar
  109. 109.
    Faedda GL, Tondo L, Baldessarini RJ. Lithium discontinuation: uncovering latent bipolar disorder? Am J Psychiatry. 2001;158:1337–9.PubMedGoogle Scholar
  110. 110.
    Faedda GL, Tondo L, Baldessarini RJ, Suppes T, Tohen M. Outcome after rapid vs. gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry. 1993;50:448–55.PubMedGoogle Scholar
  111. 111.
    Fassi G, Igoa A, Liste OA. [Valproate-induced hyperammonemic encephalopathy: review of cases in the psychiatric setting (Spanish)]. Vertex. 2008;19:371–7.PubMedGoogle Scholar
  112. 112.
    Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol. 2002;22:379–87.PubMedGoogle Scholar
  113. 113.
    Fieve RR, Kumbaraci T, Dunner DL. Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients. Am J Psychiatry. 1976;133:925–9.PubMedGoogle Scholar
  114. 114.
    Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet. 1995;29:172–91.PubMedGoogle Scholar
  115. 115.
    Fleisher AS, Truran D, Mai JT, Langbaum JB, Aisen PS, Cummings JL, et al. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology. 2011;77:1263–71.PubMedGoogle Scholar
  116. 116.
    Focosi D, Azzarà A, Kast RE, Carulli G, Petrini M. Lithium and hematology: established and proposed uses. J Leukoc Biol. 2009;85:20–8.PubMedGoogle Scholar
  117. 117.
    Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomized controlled trial. Br J Psychiatry. 2011;198:351–6.PubMedGoogle Scholar
  118. 118.
    Frassetto F, Tourneur Martel F, Barjhoux CE, Villier C, Bot BL, Vincent F. Goiter in a newborn exposed to lithium in utero. Ann Pharmacother. 2002;36:1745–8.PubMedGoogle Scholar
  119. 119.
    Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, et al. Increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry. 2000;61:9–15.PubMedGoogle Scholar
  120. 120.
    Fumarola A, Di Fiore A, Dainelli M, Grani G, Calvanese A. Medical treatment of hyperthyroidism: state of the art. Exp Clin Endocrinol Diabetes. 2010;118:678–84.PubMedGoogle Scholar
  121. 121.
    Galbally M, Roberts M, Buist A. Mood-stabilizers in pregnancy: systematic review. Aust N Z J Psychiatry. 2010;44:967–77.PubMedGoogle Scholar
  122. 122.
    Garbutt JC, Gillette GM. Apparent complex partial seizures in a bipolar patient after withdrawal of carbamazepine. J Clin Psychiatry. 1988;49:410–1.PubMedGoogle Scholar
  123. 123.
    Garrod AB. Treatise on the Nature and Treatment of Gout and Rheumatic Gout. London: Walton & Maberly; 1859.Google Scholar
  124. 124.
    Gaynes BN, Lux LJ, Lloyd SW, Hansen RA, Gartlehner G, Keener P, et al., editors. Nonpharmacologic Interventions for Treatment-Resistant Depression in Adults. Rockville, MD: US Agency for Healthcare Research and Quality, AHRQ Comparative Effectiveness Reviews, Report No. 11-EHC056-EF; 2011.Google Scholar
  125. 125.
    Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161:217–22.PubMedGoogle Scholar
  126. 126.
    Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomized open-label trial. Lancet. 2010;375:385–95.PubMedGoogle Scholar
  127. 127.
    Gelenberg AJ, Kane JM, Keller MB, Lavori P, Rosenbaum JF, Cole K, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med. 1989;321:1489–93.PubMedGoogle Scholar
  128. 128.
    George MS, Ward Jr HE, Ninan PT, Pollack M, Nahas Z, Anderson B, et al. Pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. Brain Stimul. 2008;1:112–21.PubMedGoogle Scholar
  129. 129.
    Gershon S, Chengappa KNR, Malhi GS. Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disord. 2009;11 (Suppl 2):34–44.PubMedGoogle Scholar
  130. 130.
    Ghaemi SN, Ostacher MM, El-Mallakh RS, Borrelli D, Baldassano CF, Kelley ME, et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry. 2010;71:372–80.PubMedGoogle Scholar
  131. 131.
    Ghaemi SN, Wingo AP, Filkowski MA, Goodwin FK, Baldessarini RJ. Effectiveness of long-term antidepressant treatment in bipolar disorder: meta-analysis. Acta Psychiatr Scand. 2008;118:347–56.PubMedGoogle Scholar
  132. 132.
    Ghannoum M, Lavergne V, Yue CS, Ayoub P, Perreault MM, Roy L. Successful treatment of lithium toxicity with sodium polystyrene sulfonate: retrospective cohort study. Clin Toxicol. 2010;48:34–41.Google Scholar
  133. 133.
    Gibbons RD, Hur K, Brown CH, Mann JJ. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry. 2009;66:1354–60.PubMedGoogle Scholar
  134. 134.
    Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161:1537–47.PubMedGoogle Scholar
  135. 135.
    Gitlin MJ, Cochran SD, Jamison KR. Maintenance lithium treatment: side effects and compliance. J Clin Psychiatry. 1989;50:127–31.PubMedGoogle Scholar
  136. 136.
    Glazer WM, Sonnenberg JG, Reinstein MJ, Akers RF. Novel, point-of-care test for lithium levels: description and reliability. J Clin Psychiatry. 2004;65:652–5.PubMedGoogle Scholar
  137. 137.
    González-Pinto A, Reed C, Novick D, Bertsch J, Haro JM. Assessment of medication adherence in a cohort of patients with bipolar disorder. Pharmacopsychiatry. 2010;43:263–70.PubMedGoogle Scholar
  138. 138.
    Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003;290:1467–73.PubMedGoogle Scholar
  139. 139.
    Goodwin FK, Jamison KR, editors. Manic Depressive Illness. 2nd ed. New York: Oxford University Press; 2007.Google Scholar
  140. 140.
    Goodwin FK, Murphy DL, Dunner DL, Bunney Jr WE. Lithium response in unipolar versus bipolar depression. Am J Psychiatry. 1972;129:44–7.PubMedGoogle Scholar
  141. 141.
    Goodwin FJ, Whitham EA, Ghaemi SN. Maintenance treatment study designs in bipolar disorder: do they demonstrate that atypical neuroleptics (antipsychotics) are mood stabilizers? CNS Drugs. 2011;25:819–27.PubMedGoogle Scholar
  142. 142.
    Gottberg E, Grondin L, Reader TA. Acute effects of lithium on catecholamines, serotonin, and their major metabolites in discrete brain regions. J Neurosci Res. 1989;22:338–45.PubMedGoogle Scholar
  143. 143.
    Gould TD, Quiroz JA, Singh J, Zarate CA, Manji HK. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry. 2004;9:734–55.PubMedGoogle Scholar
  144. 144.
    Grandjean EM, Aubry J-M. Lithium: updated human knowledge using an evidence-based approach (parts I, II, III). CNS Drugs. 2009;23:225–40; 331–49; 397–418.Google Scholar
  145. 145.
    Greenhill SD, Jones RS. Diverse antiepileptic drugs increase the ratio of background synaptic inhibition to excitation and decrease neuronal excitability in neurones of the rat entorhinal cortex in vitro. Neuroscience. 2010;167:456–74.PubMedGoogle Scholar
  146. 146.
    Grof P, Muller-Oerlinghausen B. Critical appraisal of lithium’s efficacy and effectiveness in the last 60 years. Bipolar Disord. 2009;11 (Suppl 2):10–9.PubMedGoogle Scholar
  147. 147.
    Grünfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol. 2009;5:270–6.PubMedGoogle Scholar
  148. 148.
    Grunze HC. Anticonvulsants in bipolar disorder. J Ment Health. 2010;19:127–41.PubMedGoogle Scholar
  149. 149.
    Gu Y, Huang LY. Gabapentin actions on N-methyl-D-aspartate receptor channels are protein kinase C-dependent. Pain. 2001;93:85–92.PubMedGoogle Scholar
  150. 150.
    Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry. 2007;68:380–3.PubMedGoogle Scholar
  151. 151.
    Haag H, Heidorn A, Haag M, Greil W. Sequence of affective polarity and lithium response: preliminary report on Munich sample. Prog Neuropsychopharmacol Biol Psychiatry. 1987;11:205–8.PubMedGoogle Scholar
  152. 152.
    Hammond WA. A Treatise on Diseases of the Nervous System. New York: D. Appleton & Co.; 1871. p. 381.Google Scholar
  153. 153.
    Hanlon LW, Romaine M. Lithium chloride as a substitute for sodium chloride in the diet; observations on its toxicity. J Am Med Assoc. 1949;139:688–92.PubMedGoogle Scholar
  154. 154.
    Hantouche EG, Akiskal HS, Lancrenon S, Chatenêt-Duchêne L. Mood stabilizer augmentation in apparently “unipolar” MDD: predictors of response in the naturalistic French national EPIDEP study. J Affect Disord. 2005;84:243–9.PubMedGoogle Scholar
  155. 155.
    Harden CL, Pennell PB, Koppel BS, Hovinga CA, Gidal B, Meador KJ, et al. Management issues for women with epilepsy: focus on pregnancy, an evidence-based review. Neurology. 2009;73:142–9.Google Scholar
  156. 156.
    Harden CL, Pennell PB, Koppel BS, Hovinga CA, Gidal B, Meador KJ, et al. Management issues for women with epilepsy: focus on pregnancy, an evidence-based review. Epilepsia. 2009;50:1247–55.PubMedGoogle Scholar
  157. 157.
    Huxley N, Parikh SU, Baldessarini RJ. Effectiveness of psychosocial treatments in bipolar disorder: State of the evidence. Harv Rev Psychiartry. 2000;8:126–40.Google Scholar
  158. 158.
    Harvey PD, Wingo AP, Burdick KE, Baldessarini RJ. Cognition and disability in bipolar disorder: lessons from schizophrenia research. Bipolar Disord. 2010;12:364–75.PubMedGoogle Scholar
  159. 159.
    Heit S, Nemeroff CB. Lithium augmentation of antidepressants in treatment-refractory depression. J Clin Psychiatry. 1998;59 (Suppl 6):28–34.PubMedGoogle Scholar
  160. 160.
    Hennen J, Baldessarini RJ. Reduced suicidal risk during treatment with clozapine: meta-analysis. Schizophr Res. 2005;73:139–45.PubMedGoogle Scholar
  161. 161.
    Henry TR. History of valproate in clinical neuroscience. Psychopharmacol Bull. 2003;37 (Suppl 2):5–16.PubMedGoogle Scholar
  162. 162.
    Herceg M, Muzinić L, Jukić V. Can we prevent blood dyscrasia (leucopenia, thrombocytopenia) and epileptic seizures induced by clozapine? Psychiatr Danub. 2010;22:85–9.PubMedGoogle Scholar
  163. 163.
    Hetmar O, Bolwig TG, Brun C, Ladefoged J, Larsen S, Rafaelsen OJ. Lithium: long-term effects on the kidney. Acta Psychiatr Scand. 1986;73:574–81.PubMedGoogle Scholar
  164. 164.
    Hetmar O, Clemmesen L, Ladefoged J, Rafaelsen OJ. Lithium: long-term effects on the kidney. Acta Psychiatr Scand. 1987;75:251–8.PubMedGoogle Scholar
  165. 165.
    Hilas O, Charnetski L. Lamotrigine-induced Stevens–Johnson syndrome. Am J Health Syst Pharm. 2007;64:273–5.PubMedGoogle Scholar
  166. 166.
    Holmes LB, Baldwin EJ, Smith CR, Habecker E, Glassman L, Wong SL, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology. 2008;70:2152–8.PubMedGoogle Scholar
  167. 167.
    Holtzheimer PE, Kelley ME, Gross RE, Filkowski MM, Garlow SJ, Barrocas A, et al. Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch Gen Psychiatry. 2012;69:150–8.Google Scholar
  168. 168.
    Howland RH, Shutt LS, Berman SR, Spotts CR, Denko T. Emerging use of technology for the treatment of depression and other neuropsychiatric disorders. Ann Clin Psychiatry. 2011;23:48–62.PubMedGoogle Scholar
  169. 169.
    Hu X, Wang J, Dong W, Fang Q, Hu L, Liu C. Meta-analysis of polycystic ovary syndrome in women taking valproate for epilepsy. Epilepsy Res. 2011;97:73–82.PubMedGoogle Scholar
  170. 170.
    Huot RL, Brennan PA, Stowe ZN, Plotsky PM, Walker EF. Negative affect in offspring of depressed mothers is predicted by infant cortisol levels at 6 months and maternal depression during pregnancy, but not postpartum. Ann N Y Acad Sci. 2004;1032:234–6.PubMedGoogle Scholar
  171. 171.
    Inoue T, Abekawa T, Nakagawa S, Suzuki K, Tanaka T, Kitaichi Y, et al. Long-term naturalistic follow-up of lithium augmentation: relevance to bipolarity. J Affect Disord. 2011;129:64–7.PubMedGoogle Scholar
  172. 172.
    Irvine RF. Inositol lipids in cell signaling. Curr Opin Cell Biol. 1992;4:212–9.PubMedGoogle Scholar
  173. 173.
    Ivković M, Damjanović A, Jovanović A, Cvetić T, Jasović-Gasić M. Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability. Psychiatr Danub. 2009;21:187–93.PubMedGoogle Scholar
  174. 174.
    Jefferson JW, Greist JH. Lithium and Bipolar Disorder: A Guide. Madison, WI: Madison Institute of Medicine; 2004.Google Scholar
  175. 175.
    Jentink J, Bakker MK, Nijenhuis CM, Wilffert B, De Jong-van den Berg LT. Does folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid? Pharmacoepidemiol Drug Saf. 2010;19:803–7.PubMedGoogle Scholar
  176. 176.
    Johannessen SI, Landmark CJ. Antiepileptic drug interactions: principles and clinical implications. Curr Neuropharmacol. 2010;8:254–67.PubMedGoogle Scholar
  177. 177.
    Joffe H. Reproductive biology and psychotropic treatments in premenopausal women with bipolar disorder. J Clin Psychiatry. 2007;68 (Suppl 9):10–5.PubMedGoogle Scholar
  178. 178.
    Joffe RT, MacQueen GM, Marriott M, Trevor Young L. Prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders. Bipolar Disord. 2004;6:62–6.PubMedGoogle Scholar
  179. 179.
    Jonathan-Ryves W, Dalton EC, Harwood AJ, Williams RS. GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid. Bipolar Disord. 2005;7:260–5.PubMedGoogle Scholar
  180. 180.
    Jones RM, Arlidge J, Gillham R, Reagu S, van den Bree M, Taylor PJ. Efficacy of mood stabilizers in the treatment of impulsive or repetitive aggression: systematic review and meta-analysis. Br J Psychiatry. 2011;198:93–8.PubMedGoogle Scholar
  181. 181.
    Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. Long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530–7.PubMedGoogle Scholar
  182. 182.
    Kakkar AK, Rehan HS, Unni KE, Gupta NK, Chopra D, Kataria D. Comparative efficacy and safety of oxcarbazepine vs. divalproex sodium in the treatment of acute mania: pilot study. Eur Psychiatry. 2009;24:178–82.PubMedGoogle Scholar
  183. 183.
    Kammerer M, Brawek B, Freiman TM, Jackisch R, Feuerstein TJ. Effects of antiepileptic drugs on glutamate release from rat and human neocortical synaptosomes. Naunyn Schmiedebergs Arch Pharmacol. 2011;383:531–42.PubMedGoogle Scholar
  184. 184.
    Kammerer M, Rassner MP, Freiman TM, Feuerstein TJ. Effects of antiepileptic drugs on GABA release from rat and human neocortical synaptosomes. Naunyn Schmiedebergs Arch Pharmacol. 2011;384:47–57.PubMedGoogle Scholar
  185. 185.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.Google Scholar
  186. 186.
    Katz RI, Chase TN, Kopin IJ. Evoked release of norepinephrine and serotonin from brain slides: inhibition by lithium. Science. 1968;162:466–7.PubMedGoogle Scholar
  187. 187.
    Keck Jr PE, Manji HK. Current and emerging treatment for acute mania and long-term prophylaxis for bipolar disorder, Chap. 77. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology–Fifth Generation of Progress. New York: Lippincott Williams & Wilkins; 2008. p. 1009–118.Google Scholar
  188. 188.
    Keck Jr PR, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry. 2002;63 (Suppl 4):3–11.PubMedGoogle Scholar
  189. 189.
    Keck Jr PE, McElroy SL, Bennett JA. Pharmacologic loading in the treatment of acute mania. Bipolar Disord. 2000;2:42–6.PubMedGoogle Scholar
  190. 190.
    Kemp DE, Ganocy SJ, Brecher M, Carlson BX, Edwards S, Eudicone JM, et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord. 2011;130:171–9.PubMedGoogle Scholar
  191. 191.
    Kennedy SH, Milev R, Giacobbe P, Ramasubbu R, Lam RW, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults: neurostimulation therapies. J Affect Disord. 2009;117 (Suppl 1):S44–53.PubMedGoogle Scholar
  192. 192.
    Ketter RA. Handbook of Diagnosis and Treatment of Bipolar Disorder. Arlington, VA: American Psychiatric Publishing; 2010.Google Scholar
  193. 193.
    Ketter TA, Citrome L, Wang PW, Culver JL, Srivastava S. Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? Acta Psychiatr Scand. 2011;123:175–89.PubMedGoogle Scholar
  194. 194.
    Ketter TA, Wang PW, Chandler RA, Alarcon AM, Becker OV, Nowakowska C, et al. Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. J Clin Psychiatry. 2005;66:642–5.PubMedGoogle Scholar
  195. 195.
    Khalsa HMK, Salvatore P, Hennen J, Tohen M, Baldessarini RJ. Suicidal events and accidents in 216 first-episode bipolar-I disorder patients: predictive factors. J Affect Disord. 2008;106:179–84.PubMedGoogle Scholar
  196. 196.
    Kidd SK, Schneider JS. Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Neuroscience. 2011;194:189–94.PubMedGoogle Scholar
  197. 197.
    Koren G. Pharmacokinetics in pregnancy; clinical significance. J Popul Ther Clin Pharmacol. 2011;18:e523–7.PubMedGoogle Scholar
  198. 198.
    Kortenoeven ML, Li Y, Shaw S, Gaeggeler HP, Rossier BC, Wetzels JF, et al. Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus. Kidney Int. 2009;76:44–53.PubMedGoogle Scholar
  199. 199.
    Koukopoulos A, Sani G, Koukopoulos AE, Manfredi G, Pacchiarotti I, Girardi P. Melancholia agitata and mixed depression. Acta Psychiatr Scand. 2007;117 (Suppl 433):50–7.Google Scholar
  200. 200.
    Koukopoulos A, Serra G, Koukopoulos AE, Reginaldi D, Serra G. Sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12 month naturalistic trial. J Affect Disord. 2011;136:163–6.PubMedGoogle Scholar
  201. 201.
    Kovacsics CE, Gottesman II, Gould TD. Lithium’s antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Annu Rev Pharmacol Toxicol. 2009;49:175–98.PubMedGoogle Scholar
  202. 202.
    Kozma C. Neonatal toxicity and transient neurodevelopmental deficits following prenatal exposure to lithium: another clinical report and a review of the literature. Am J Med Genet A. 2005;132:441–4.PubMedGoogle Scholar
  203. 203.
    Krauthammer C, Klerman GL. Secondary mania: manic syndromes associated with antecedent physical illness or drugs. Arch Gen Psychiatry. 1978;35:1333–9.PubMedGoogle Scholar
  204. 204.
    Kukopulos A, Reginaldi D, Girardi P, Tondo L. Course of manic-depressive recurrences under lithium. Compr Psychiatry. 1975;16:517–24.PubMedGoogle Scholar
  205. 205.
    Kukuljan M, Vergara L, Stojilkovic SS. Modulation of the kinetics of inositol 1,4,5-trisphosphate-Induced [Ca2+]i oscillations by calcium entry in pituitary gonadotrophs. Biophys J. 1997;72:698–707.PubMedGoogle Scholar
  206. 206.
    Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the management of acute mania: results of four double-blind, placebo-controlled trials. Bipolar Disord. 2006;8:15–27.PubMedGoogle Scholar
  207. 207.
    Lam RW, Chan P, Wilkins-Ho M, Yatham LN. Repetitive transcranial magnetic stimulation for treatment-resistant depression: systematic review and meta-analysis. Can J Psychiatry. 2008;53:621–31.PubMedGoogle Scholar
  208. 208.
    Lambert PA, Carraz G, Borselli S, Carbel S. [Neuropsychotropic action of a new anti-epileptic agent: depamide (French)]. Ann Med Psychol (Paris). 1966;124:707–10.Google Scholar
  209. 209.
    Lasser RA, Baldessarini RJ. Thyroid hormones in depressive disorders: reappraisal of clinical utility. Harv Rev Psychiatry. 1997;4:291–305.PubMedGoogle Scholar
  210. 210.
    Lauterbach EC, Mendez MF. Psychopharmacological neuroprotection in neurodegenerative diseases. J Neuropsychiatry Clin Neurosci. 2011;23:242–60.PubMedGoogle Scholar
  211. 211.
    Lauterbach EC, Victoroff J, Coburn KL, Shillcutt SD, Doonan SM, Mendez MF. Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J Neuropsychiatry Clin Neurosci. 2010;22:8–18.PubMedGoogle Scholar
  212. 212.
    Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23:723–33.PubMedGoogle Scholar
  213. 213.
    Lepkifker E, Iancu I, Horesh N, Strous RD, Kotler M. Lithium therapy for unipolar and bipolar depression among the middle-aged and older adult patient subpopulation. Depress Anxiety. 2007;24:571–6.PubMedGoogle Scholar
  214. 214.
    Levin GM, Grum C, Eisele G. Effect of over-the-counter dosages of naproxen sodium and acetaminophen on plasma lithium concentrations in normal volunteers. J Clin Psychopharmacol. 1998;18:237–40.PubMedGoogle Scholar
  215. 215.
    Levy RH, Mattson RH, Meldrum BS, Perucca E, editors. Antiepileptic Drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002.Google Scholar
  216. 216.
    Livingstone C, Rampes H. Lithium: review of its metabolic adverse effects. J Psychopharmacol. 2006;20:347–55.PubMedGoogle Scholar
  217. 217.
    Lorenzo LS, Vázquez GH, Zaratiegui RM, Baldessarini RJ. Antidepressants for bipolar disorder. J Affect Disord. Hum Psychopharmacol 2012; in press.Google Scholar
  218. 218.
    Machado-Vieira R, Manji HK, Zarate Jr CA. Role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord. 2009;11 (Suppl 2):92–109.PubMedGoogle Scholar
  219. 219.
    Machado-Vieira R, Salvadore G, Diaz-Granados N, Ibrahim L, Latov D, Wheeler-Castillo C, et al. New therapeutic targets for mood disorders. ScientificWorldJournal. 2010;13:713–26.Google Scholar
  220. 220.
    Mack A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm. 2003;9:559–68.PubMedGoogle Scholar
  221. 221.
    MacNamara JO. Pharmacotherapy of the epilepsies, Chap. 21. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. New York: McGraw Hill; 2011. p. 582–607.Google Scholar
  222. 222.
    Maj M, Starace F, Nolfe G, Kemali D. Minimum plasma lithium levels required for effective prophylaxis in DSM III bipolar disorder: a prospective study. Pharmacopsychiatry. 1986;19:420–3.PubMedGoogle Scholar
  223. 223.
    Manji HK, Moore GJ, Chen G. Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilizers. Br J Psychiatry. 2001;41(Suppl):s107–19.Google Scholar
  224. 224.
    Marangell LB, Dennehy EB, Wisniewski SR, Bauer MS, Miyahara S, Allen MH, et al. Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder. J Clin Psychiatry. 2008;69:916–22.PubMedGoogle Scholar
  225. 225.
    Marangell LB, Martinez M, Jurdi RA, Zboyan H. Neurostimulation therapies in depression: review of new modalities. Acta Psychiatr Scand. 2007;116:174–81.PubMedGoogle Scholar
  226. 226.
    Markham JA, Koenig JI. Prenatal stress: role in psychotic and depressive diseases. Psychopharmacology. 2011;214:89–106.PubMedGoogle Scholar
  227. 227.
    Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008;33:2080–92.PubMedGoogle Scholar
  228. 228.
    Mazza M, Di Nicola M, Martinotti G, Taranto C, Pozzi G, Conte G, et al. Oxcarbazepine in bipolar disorder: critical literature review. Expert Opin Pharmacother. 2007;8:649–56.PubMedGoogle Scholar
  229. 229.
    McIntyre RS, Yoon J, Jerrell JM, Liauw SS. Aripiprazole for the maintenance treatment of bipolar disorder: review of available evidence. Neuropsychiatr Dis Treat. 2011;7:319–23.PubMedGoogle Scholar
  230. 230.
    McKnight RF, Adida M, Budge K, Stockton S, Boodwin GM, Geddes JR. Lithium toxicity profile: systematic review and meta-analysis. Lancet. 2012;379:721–8.Google Scholar
  231. 231.
    McNamara J. Pharmacotherapy of the epilepsies, Chap. 21. In: Brunton L, Chabner B, Knollman B, editors. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill; 2011. p. 782–807.Google Scholar
  232. 232.
    Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem J. 1998;332:281–92.PubMedGoogle Scholar
  233. 233.
    Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia. Arch Gen Psychiatry. 2003;60:82–91.PubMedGoogle Scholar
  234. 234.
    Mendels J. Role of lithium as an antidepressant. Mod Probl Pharmacopsychiatry. 1982;18:138–44.PubMedGoogle Scholar
  235. 235.
    Meyer JM. Pharmacotherapy of psychosis and mania, Chap. 16. In: Brunton L, Chabner B, Knollman B, editors. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill; 2011. p. 417–55.Google Scholar
  236. 236.
    Meyer JM, Dollarhide A, Tuan IL. Lithium toxicity after switch from fosinopril to lisinopril. Int Clin Psychopharmacol. 2005;20:115–8.PubMedGoogle Scholar
  237. 237.
    Meunier H, Carraz G, Meunier Y, Eymard P, Aimard M. Propriétés pharmacodynamiques de l’acidee n-dipropylacetique. Therapie. 1963;18:435–8.PubMedGoogle Scholar
  238. 238.
    Miklowitz DJ. Fuctional impairment, stress, and psychosial intervention in bipolar disorder. Curr Psychiatry Rep. 2011;13:504–12.PubMedGoogle Scholar
  239. 239.
    Mirin SM, Schatzberg AF, Creasey DE. Hypomania and mania after withdrawal of tricyclic antidepressants. Am J Psychiatry. 1981;138:87–9.PubMedGoogle Scholar
  240. 240.
    Mischoulon D, Nierenberg AA, Kizilbash L, Rosenbaum JF, Fava M. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry. 2000;45:476–81.PubMedGoogle Scholar
  241. 241.
    Modell JG, Lenox RH, Weiner S. Inpatient clinical trial of lorazepam for the management of manic agitation. J Clin Psychopharmacol. 1985;5:109–13.PubMedGoogle Scholar
  242. 242.
    Mohr P, Rodriguez M, Slavíčková A, Hanka J. Application of vagus nerve stimulation and deep brain stimulation in depression. Neuropsychobiology. 2011;64:170–81.PubMedGoogle Scholar
  243. 243.
    Monk C, Fitelson EM, Werner E. Mood disorders and their pharmacological treatment during pregnancy: is the future child affected? Pediatr Res. 2011;69:3R–10R.PubMedGoogle Scholar
  244. 244.
    Moore CM, Demopulos CM, Henry ME, Steingard RJ, Zamvil L, Katic A, et al. Brain-to-serum lithium ratio and age: in vivo magnetic resonance spectroscopy study. Am J Psychiatry. 2002;159:1240–2.PubMedGoogle Scholar
  245. 245.
    Müller-Oerlinghausen B, Felber W, Berghöfer A, Lauterbach E, Ahrens B. Impact of lithium long-term medication on suicidal behavior and mortality of bipolar patients. Arch Suicide Res. 2005;9:307–19.PubMedGoogle Scholar
  246. 246.
    Müller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: a mini-review. Neuropsychobiology. 2010;62:43–9.PubMedGoogle Scholar
  247. 247.
    Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 2010;67:26–36.PubMedGoogle Scholar
  248. 248.
    Muzina DJ. Pharmacologic treatment of rapid cycling and mixed states in bipolar disorder: an argument for the use of lithium. Bipolar Disord. 2009;11 (Suppl 2):84–91.PubMedGoogle Scholar
  249. 249.
    Muzina DJ, Gao K, Kemp DE, Khalife S, Ganocy SJ, Chan PK, et al. Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2011;72:813–9.PubMedGoogle Scholar
  250. 250.
    Narayan V, Haddad PM. Antidepressant discontinuation manic states: critical review of the literature and suggested diagnostic criteria. J Psychopharmacol. 2011;25:306–13.PubMedGoogle Scholar
  251. 251.
    Newport DJ, Stowe ZN, Viguera AC, Calamaras MR, Juric S, Knight B, et al. Lamotrigine in bipolar disorder: efficacy during pregnancy. Bipolar Disord. 2008;10:432–6.PubMedGoogle Scholar
  252. 252.
    Nguyen HT, Sharma V, McIntyre RS. Teratogenesis associated with antibipolar agents. Adv Ther. 2009;26:281–94.PubMedGoogle Scholar
  253. 253.
    Novick DM, Swartz HA, Frank E. Suicide attempts in bipolar I and bipolar II disorder: review and meta-analysis of the evidence. Bipolar Disord. 2010;12:1–9.PubMedGoogle Scholar
  254. 254.
    Oedegaard KJ, Dilsaver SC, Hundal O, Riise T, Lund A, Akiskal HS, et al. Are migraine and bipolar disorders comorbid phenomena?: findings from a pharmacoepidemiological study using the norwegian prescription database. J Clin Psychopharmacol. 2011;31:734–9.PubMedGoogle Scholar
  255. 255.
    Okada M, Yoshida S, Zhu G, Hirose S, Kaneko S. Biphasic actions of topiramate on monoamine exocytosis associated with both soluble N-ethylmaleimide-sensitive factor attachment protein receptors and Ca2+-induced Ca2+-releasing systems. Neuroscience. 2005;134:233–46.PubMedGoogle Scholar
  256. 256.
    Okuma T. [History of investigation on the mood-stabilizing effect of carbamazepine in Japan (Japanese)]. Seishin Shinkeigaku Zasshi. 2002;104:647–55.PubMedGoogle Scholar
  257. 257.
    Okuma T, Kishimoto A, Inoue K, Matsumoto H, Ogura A. Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis: preliminary report. Folia Psychiatr Neurol Jpn. 1973;27:283–97.PubMedGoogle Scholar
  258. 258.
    Oquendo MA, Galfalvy HC, Currier D, Grunebaum MF, Sher L, Sullivan GM, et al. Treatment of suicide attempters with bipolar disorder: randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. Am J Psychiatry. 2011;168:1050–6.PubMedGoogle Scholar
  259. 259.
    Ösby U, Brandt L, Correia N, Ekbom A, Sparén P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844–50.PubMedGoogle Scholar
  260. 260.
    Ouyang DY, Ji YH, Saltis M, Xu LH, Zhang YT, Zha QB, et al. Valproic acid synergistically enhances the cytotoxicity of gossypol in DU145 prostate cancer cells: an iTRTAQ-based quantitative proteomic analysis. J Proteomics. 2011;74:2180–93.PubMedGoogle Scholar
  261. 261.
    Ozerdem A, Schmidt ME, Manji HK, Risinger RC, Potter WZ. Chronic lithium administration enhances noradrenergic responses to intravenous administration of the alpha-2 antagonist idazoxan in healthy volunteers. J Clin Psychopharmacol. 2004;24:150–4.PubMedGoogle Scholar
  262. 262.
    Pacchiarotti I, Valentí M, Bonnin CM, Rosa AR, Murru A, Kotzalidis GD, et al. Factors associated with initial treatment response with antidepressants in bipolar disorder. Eur Neuropsychopharmacol. 2011;21:362–9.PubMedGoogle Scholar
  263. 263.
    Pacchiarotti I, Valentí M, Colom F, Rosa AR, Nivoli AM, Murru A, et al. Differential outcome of bipolar patients receiving antidepressant monotherapy versus combination with an antimanic drug. J Affect Disord. 2011;129:321–6.PubMedGoogle Scholar
  264. 264.
    Pacchiarotti I, Mazzarini L, Kotzalidis GD, Valentí M, Nivoli AM, Sani G, et al. Mania and depression: mixed, not stirred. J Affect Disord. 2011;133:105–13.PubMedGoogle Scholar
  265. 265.
    Pasquali L, Busceti CL, Fulceri F, Paparelli A, Fornai F. Intracellular pathways underlying the effects of lithium. Behav Pharmacol. 2010;21:473–92.PubMedGoogle Scholar
  266. 266.
    Pasquini M, Picardi A, Speca A, Orlandi V, Tarsitani L, Morosini P, et al. Combining an SSRI with an anticonvulsant in depressed patients with dysphoric mood: open study. Clin Pract Epidemiol Ment Health. 2007;3:3–15.PubMedGoogle Scholar
  267. 267.
    Patorno E, Bohn RL, Wahl PM, Avorn J, Patrick AR, Liu J, Scheeweiss S. Anticonvulsant medication and the risk of suicide, attempted suicide, or acident death. JAMA. 2010;303:1401–9.PubMedGoogle Scholar
  268. 268.
    Paykel ES, Abbott R, Morriss R, Hayhurst H, Scott J. Sub-syndromal and syndromal symptoms in the longitudinal course of bipolar disorder. Br J Psychiatry. 2006;189:118–23.PubMedGoogle Scholar
  269. 269.
    Peng L, Li B, Du T, Wang F, Hertz L. Does conventional anti-bipolar and antidepressant drug therapy reduce NMDA-mediated neuronal excitation by downregulating astrocytic GluK2 function? Pharmacol Biochem Behav. 2012;100:712–25.PubMedGoogle Scholar
  270. 270.
    Pennell PB, Peng L, Newport DJ, Ritchie JC, Koganti A, Holley DK, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology. 2008;70:2130–6.PubMedGoogle Scholar
  271. 271.
    Pérez J, Baldessarini RJ, Cruz N, Salvatore P, Vieta E. Andrés Piquer-Arrufat (1711–1772): contributions of an eighteenth-century Spanish physician to the concept of manic-depressive illness. Harv Rev Psychiatry. 2011;19:68–77.PubMedGoogle Scholar
  272. 272.
    Perlis RH, Sachs GS, Lafer B, Otto MW, Faraone SV, Kane JM, et al. Effect of abrupt change from standard to low serum levels of lithium: reanalysis of double-blind lithium maintenance data. Am J Psychiatry. 2002;159:1155–9.PubMedGoogle Scholar
  273. 273.
    Perris C. Distinction between unipolar and bipolar mood disorders: 25-years perspective. Encéphale. 1992;18 (Suppl 1):9–13.PubMedGoogle Scholar
  274. 274.
    Perrott J, Murphy NG, Zed PJ. L-carnitine for acute valproic acid overdose: systematic review of published cases. Ann Pharmacother. 2010;44:1287–93.PubMedGoogle Scholar
  275. 275.
    Pichot P. Tracing the origins of bipolar disorder. J Affect Disord. 2006;96:145–8.PubMedGoogle Scholar
  276. 276.
    Pompili M, Baldessarini RJ. Risk of suicidal behavior with antiepileptic drugs. Nat Rev Neurol. 2010;6:651–3.PubMedGoogle Scholar
  277. 277.
    Popovic D, Reinares M, Amann B, Salmero M, Vieta E. Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology. 2011;213:657–67.PubMedGoogle Scholar
  278. 278.
    Popovic D, Reinares M, Goikolea HM, Bonnin CM, Gonzalez-Pinto A, Vieta E. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol. 2012;22:339–46.PubMedGoogle Scholar
  279. 279.
    Post RM, Altshuler LL, Frye MA, Suppes T, Keck Jr PE, McElroy SL, et al. Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. J Clin Psychiatry. 2010;71:1176–86.PubMedGoogle Scholar
  280. 280.
    Post RM, Denicoff KD, Leverich GS, Altshuler LL, Frye MA, Suppes TM, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry. 2003;64:680–90.PubMedGoogle Scholar
  281. 281.
    Post RM, Frye MA, Denicoff KD, Leverich GS, Dunn RT, Osuch EA, et al. Emerging trends in the treatment of rapid cycling bipolar disorder: selected review. Bipolar Disord. 2000;2:305–15.PubMedGoogle Scholar
  282. 282.
    Post RM, Ketter TA, Uhde T, Ballenger JC. Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. CNS Drugs. 2007;21:47–71.PubMedGoogle Scholar
  283. 283.
    Post RM, Leverich GS, Kupka RW, Keck Jr PE, McElroy SL, Altshuler LL, et al. Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clin Psychiatry. 2010;71:864–72.PubMedGoogle Scholar
  284. 284.
    Quiroz JA, Gould TD, Manji HK. Molecular effects of lithium. Mol Interv. 2004;4:259–72.PubMedGoogle Scholar
  285. 285.
    Rao JS, Rapoport SI. Mood-stabilizers target the brain arachidonic acid cascade. Curr Mol Pharmacol. 2009;2:207–14.PubMedGoogle Scholar
  286. 286.
    Rapiejko PJ, Northup JK, Evans T, Brown JE, Malbon CC. G-proteins of fat-cells: role in hormonal regulation of intracellular inositol-1,4,5-trisphosphate. Biochem J. 1986;240:35–40.PubMedGoogle Scholar
  287. 287.
    Rapoport SI. Arachidonic acid and the brain. J Nutr. 2008;138:2515–20.PubMedGoogle Scholar
  288. 288.
    Rapoport SI, Basselin M, Kim HW, Rao JS. Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev. 2009;61:185–209.PubMedGoogle Scholar
  289. 289.
    Rosa AR, Fountoulakis K, Siamouli M, Gonda X, Vieta E. Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials. CNS Neurosci Ther. 2011;17:167–77.PubMedGoogle Scholar
  290. 290.
    Rybakowski JK. Bipolarity and inadequate response to antidepressant drugs: clinical and psychopharmacological perspective. J Affect Disord. 2012;136:e13–9.PubMedGoogle Scholar
  291. 291.
    Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356:1711–22.PubMedGoogle Scholar
  292. 292.
    Salvatore P, Baldessarini RJ, Centorrino F, Egli S, Albert M, Gerhard A, et al. Weygandt’s, The Manic-Depressive Mixed States: translation and commentary on its significance in the evolution of the concept of bipolar manic-depressive disorder. Harv Rev Psychiatry. 2002;10:255–75.PubMedGoogle Scholar
  293. 293.
    Salvatore P, Baldessarini RJ, Tohen M, Khalsa HMK, Perez Sanchez-Toledo J, Zarate Jr CA, et al. Two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry. 2009;70:458–66.PubMedGoogle Scholar
  294. 294.
    Salvatore P, Baldessarini RJ, Tohen M, Khalsa HM, Sanchez-Toledo JP, Zarate Jr CA, et al. Two-year stability of ICD-10 diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry. 2011;72:183–93.PubMedGoogle Scholar
  295. 295.
    Sanches M, Newberg AR, Soares JC. Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2010;15:453–66.PubMedGoogle Scholar
  296. 296.
    Sanchez-Moreno J, Martinez-Aran A, Tabarés-Seisedos R, Torrent C, Vieta E, Ayuso-Mateos JL. Functioning and disability in bipolar disorder: an extensive review. Psychotherapy Psychosom. 2009;28:285–97.Google Scholar
  297. 297.
    Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012;73:81–6.PubMedGoogle Scholar
  298. 298.
    Sastre E, Nicolay A, Bruguerolle B, Portugal H. Effect of lithium on norepinephrine metabolic pathways. Life Sci. 2005;77:758–67.PubMedGoogle Scholar
  299. 299.
    Schioldann J. “On periodical depressions and their pathogenesis” by Carl Lange (1886). Hist Psychiatry. 2011;22:108–30.PubMedGoogle Scholar
  300. 300.
    Schöttle D, Huber CG, Bock T, Meyer TD. Psychotherapy for bipolar disorder: review of the most recent studies. Curr Opin Psychiatry. 2011;24:549–55.PubMedGoogle Scholar
  301. 301.
    Sedler MJ. Falret’s discovery: the origin of the concept of bipolar affective illness. Am J Psychiatry. 1983;140:1127–33.PubMedGoogle Scholar
  302. 302.
    Segredon I, Xenitides K, Panagiotopoulos M, Bochtsou V, Antoniadou O, Livaditis M. Group psychosocial interventions for adults with schizophrenia and bipolar illness: the evidence base in light of publications between 1985 and 2006. Int J Soc Psychitry. 2012;58:229–38.Google Scholar
  303. 303.
    Seo HJ, Chiesa A, Lee SJ, Patkar AA, Han C, Masand PS, et al. Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. Clin Neuropharmacol. 2011;34:3947.Google Scholar
  304. 304.
    Serretti A, Drago A, De Ronchi D. Lithium pharmacodynamics and pharmacogenetics: focus on inositol mono phosphatase (IMPase), inositol polyphosphatase (IPPase) and glycogen synthase kinase-3-beta (GSK-3-beta). Curr Med Chem. 2009;16:1917–48.PubMedGoogle Scholar
  305. 305.
    Schou M. Forty years of lithium treatment. Arch Gen Psychiatry. 1997;54:9–15.PubMedGoogle Scholar
  306. 306.
    Shaldubina A, Agam G, Belmaker RH. Mechanism of lithium action: state of the art, ten years later. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:855–66.PubMedGoogle Scholar
  307. 307.
    Shaltiel G, Mark S, Kofman O, Belmaker RH, Agam G. Effect of valproate derivatives on human brain myoinositol-1-phosphate (MIP) synthase activity and amphetamine-induced rearing. Pharmacol Rep. 2007;59:402–7.PubMedGoogle Scholar
  308. 308.
    Shelton RC. Mood-stabilizing drugs in depression. J Clin Psychiatry. 1999;60 (Suppl 5):37–42.PubMedGoogle Scholar
  309. 309.
    Shorter E. History of lithium therapy. Bipolar Disord. 2009;11 (Suppl 2):4–9.PubMedGoogle Scholar
  310. 310.
    Sidor MM, MacQueen GM. Antidepressants for the acute treatment of bipolar depression: systematic review and meta-analysis. J Clin Psychiatry. 2011;72:156–67.PubMedGoogle Scholar
  311. 311.
    Siegel AJ, Baldessarini RJ, Klepser MB, McDonald JC. Primary and drug-induced disorders of water homeostasis in psychiatric patients: principles of diagnosis and management. Harv Rev Psychiatry. 1998;6:190–200.PubMedGoogle Scholar
  312. 312.
    Singh R, Mukhopadhyay K. Survival analysis in clinical trials: basics and must-know areas. Perspect Clin Res. 2011;2:145–8.PubMedGoogle Scholar
  313. 313.
    Sirivella S, Gielchinsky I. Surgery of the Ebstein’s anomaly: early and late outcomes. J Card Surg. 2011;26:227–33.PubMedGoogle Scholar
  314. 314.
    Smith LA, Cornelius VR, Azorin JM, Perugi G, Vieta E, Young AH, et al. Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord. 2010;122:1–9.PubMedGoogle Scholar
  315. 315.
    Smith FE, Cousins DA, Thelwall PE, Ferrier IN, Blamire AM. Quantitative lithium magnetic resonance spectroscopy in the normal human brain on a 3-T clinical scanner. Magn Reson Med. 2011;66:945–9.PubMedGoogle Scholar
  316. 316.
    Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. Omega-3 fatty acids in bipolar disorder: preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999;56:407–12.PubMedGoogle Scholar
  317. 317.
    Stoner SC, Nelson LA, Lea JW, Marken PA, Sommi RW, Dahmen MM. Historical review of carbamazepine for the treatment of bipolar disorder. Pharmacotherapy. 2007;27:68–88.PubMedGoogle Scholar
  318. 318.
    Soufia M, Aoun J, Gorsane MA, Krebs MO. [SSRIs and pregnancy: a review of the literature (French)]. Encéphale. 2010;36:513–6.PubMedGoogle Scholar
  319. 319.
    Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry. 1991;48:1082–8.PubMedGoogle Scholar
  320. 320.
    Svendsen KB, Bech JN, Sørensen TB, Pedersen EB. A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, renin, vasopressin and urinary excretion of albumin and alpha-glutathione-S-transferase in healthy subjects: placebo-controlled cross-over study. Eur J Clin Pharmacol. 2000;56:383–8.PubMedGoogle Scholar
  321. 321.
    Swann AC. The strong relationship between bipolar and substance-use disorder. Ann N Y Acad Sci. 2010;1187:276–93.PubMedGoogle Scholar
  322. 322.
    Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry. 2011;72:356–66.PubMedGoogle Scholar
  323. 323.
    Tamura M, Sajo M, Kakita A, Matsuki N, Koyama R. Prenatal stress inhibits neuronal maturation through downregulation of mineralocorticoid receptors. J Neurosci. 2011;31:11505–14.PubMedGoogle Scholar
  324. 324.
    Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011;68:853–61.PubMedGoogle Scholar
  325. 325.
    Tarr GP, Glue P, Herbison P. Comparative efficacy an acceptability of mood-stabilizer and second-generation antipsychotic monotherapy for acute mania: systematic review and meta-analysis. J Affect Disord. 2011;134:14–9.PubMedGoogle Scholar
  326. 326.
    Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, et al. Randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68:224–36.PubMedGoogle Scholar
  327. 327.
    Thomas SP, Nandhra HS, Jayaraman A. Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD). J Ment Health. 2010;19:168–75.PubMedGoogle Scholar
  328. 328.
    Tomson T, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin Pharmacokinet. 2007;46:209–19.PubMedGoogle Scholar
  329. 329.
    Tomson T, Battino D. Teratogenic effects of antiepileptic medications. Neurol Clin. 2009;27:993–1002.PubMedGoogle Scholar
  330. 330.
    Trede K, Viguera AC, Bottéro A, Baldessarini RJ. Treatise on insanity in pregnant, postpartum, and lactating women by Louis-Victor Marcé (1858): commentary. Harv Rev Psychiatry. 2009;17:157–65.PubMedGoogle Scholar
  331. 331.
    Tohen M, Zarate Jr CA, Hennen J, Khalsa HM, Strakowski SM, Gebre-Medhin P, et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry. 2003;160:2099–107.PubMedGoogle Scholar
  332. 332.
    Tondo L, Baldessarini RJ, Floris G, Tondo L, Baldessarini RJ. Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. Br J Psychiatry. 2001;178 (Suppl 40):184–90.Google Scholar
  333. 333.
    Tondo L, Baldessarini RJ, Vázquez G, Lepri B, Visioli C. Clinical responses to treatment in acutely depressed patients with bipolar versus unipolar major affective disorders. Acta Psychiatr Scand. 2012; in press.Google Scholar
  334. 334.
    Tondo L, Hennen J, Baldessarini RJ. Reduced suicide risk with long-term lithium treatment in major affective illness: meta-analysis. Acta Psychiatr Scand. 2001;104:163–72.PubMedGoogle Scholar
  335. 335.
    Tondo L, Hennen J, Baldessarini RJ. Meta-analysis of treatment responses of rapid-cycling and non-rapid-cycling bipolar disorder patients. Acta Psychiatr Scand. 2003;104:4–14.Google Scholar
  336. 336.
    Tondo L, Isacsson G, Baldessarini RJ. Suicide in bipolar disorder: risk and prevention. CNS Drugs. 2003;17:491–511.PubMedGoogle Scholar
  337. 337.
    Tondo L, Lepri B, Baldessarini RJ. Risks of suicidal ideation, attempts and suicides among 2826 men and women with types I and II bipolar, and recurrent major depressive disorders. Acta Psychiatr Scand. 2007;116:419–28.PubMedGoogle Scholar
  338. 338.
    Tondo L, Lepri B, Cruz N, Baldessarini RJ. Age at onset in 3014 Sardinian bipolar and major depressive disorder patients. Acta Psychiatr Scand. 2010;121:446–52.PubMedGoogle Scholar
  339. 339.
    Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant-treatment: comprehensive meta-analytic review. Acta Psychiatr Scand. 2010;121:404–14.PubMedGoogle Scholar
  340. 340.
    Trede K, Salvatore P, Baethge C, Gerhard A, Maggini C, Baldessarini RJ. Manic-depressive illness: evolution in Kraepelin’s textbook, 1883–1926. Harv Rev Psychiatry. 2005;13:155–78.PubMedGoogle Scholar
  341. 341.
    Tripathi BM, Majumder P. Lactating mother and psychotropic drugs. Mens Sana Monogr. 2010;8:83–95.PubMedGoogle Scholar
  342. 342.
    Tsai AC, Rosenlicht NZ, Jureidini JN, Parry PI, Spielman GI, Healy D. Systematic search of the literature reveals limited evidence to support use of aripiprazole, a second-generation antipsychotic medication, in maintenance therapy of bipolar disorder, despite widespread use. PLoS Med. 2011;8:e1000434.PubMedGoogle Scholar
  343. 343.
    Undurraga J, Baldessarini RJ, Valenti M, Pacchiarotti I, Tondo L, Vázquez G, Vieta E. Bipolar depression: clinical correlates of receiving antidepressants. J Affect Disord. 2012;139:89–93.Google Scholar
  344. 344.
    Underwood TW, Frye CB. Drug-induced pancreatitis. Clin Pharm. 1993;12:440–8.PubMedGoogle Scholar
  345. 345.
    Vajda FJ, Graham J, Roten A, Lander CM, O’Brien TJ, Eadie M. Teratogenicity of the newer antiepileptic drugs: the Australian experience. J Clin Neurosci. 2012;19:57–9.PubMedGoogle Scholar
  346. 346.
    Valenti M, Benabarre A, Garcia-Amador M, Molina O, Bernardo M, Vieta E. Electroconvulsive therapy in the treatment of mixed states in bipolar disorder. Eur Psychiatry. 2008;23:53–6.PubMedGoogle Scholar
  347. 347.
    Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: review. Epilepsia. 1994;35:181–8.PubMedGoogle Scholar
  348. 348.
    van der Loos ML, Mulder P, Hartong EG, Blom MB, Vergouwen AC, van Noorden MS, et al. Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: randomized, placebo-controlled trial with a novel design. Bipolar Disord. 2011;13:111–7.PubMedGoogle Scholar
  349. 349.
    van Melick EJ, Wilting I, Souverein PC, Egberts TC. Differences in lithium use patterns in the Netherlands: comparing middle-aged and older patients in a database study. Am J Geriatr Pharmacother. 2012 [Epub ahead of print, March 12].Google Scholar
  350. 350.
    Vasudev K, Macritchie K, Geddes J, Watson S, Young A. Topiramate for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev. 2008;1:CD003384.Google Scholar
  351. 351.
    Vasudev A, Macritchie K, Watson S, Geddes JR, Young AH. Oxcarbazepine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. 2008;1:CD005171.Google Scholar
  352. 352.
    Vázquez G, Baldessarini RJ, Yildiz A, Tamayo J, Tondo L, Salvatore P. Multi-site international collaborative clinical trials in mania: commentary. Int J Neuropsychopharmacol. 2011;14:1013–6.PubMedGoogle Scholar
  353. 353.
    Vázquez G, Tondo L, Baldessarini RJ. Comparison of antidepressant responses in patients with bipolar vs. unipolar depression: meta-analytic review. Pharmacopsychiatry. 2011;44: 21–6.PubMedGoogle Scholar
  354. 354.
    Ventriglio A, Vincenti A, Centorrino F, Talamo A, Fitzmaurice G, Baldessarini RJ. Use of mood-stabilizers for hospitalized adult psychotic and bipolar disorder patients. Int Clin Psychopharmacol. 2011;25:88–95.Google Scholar
  355. 355.
    Vestergaard P. Skeletal effects of central nervous system active drugs: anxiolytics, sedatives, antidepressants, lithium and neuroleptics. Curr Drug Saf. 2008;3:185–9.PubMedGoogle Scholar
  356. 356.
    Vieta E. Bipolar mixed states and their treatment. Expert Rev Neurother. 2005;5:63–8.PubMedGoogle Scholar
  357. 357.
    Vieta E, Cruz N, García-Campayo J, de Arce R, Manuel Crespo J, Vallès V, et al. Double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. Int J Neuropsychopharmacol. 2008;11:445–52.PubMedGoogle Scholar
  358. 358.
    Vieta E, Günther O, Locklear J, Ekman M, Miltenburger C, Chatterton ML, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2011;14:1029–49.PubMedGoogle Scholar
  359. 359.
    Vieta E, Locklear J, Günther O, Ekman M, Miltenburger C, Chatterton ML, et al. Treatment options for bipolar depression: systematic review of randomized, controlled trials. J Clin Psychopharmacol. 2010;30:579–90.PubMedGoogle Scholar
  360. 360.
    Vieta E, Owen R, Baudelet C, McQuade RD, Sanchez R, Marcus RN. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium orvalproate in bipolar mania: 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin. 2010;26:1485–96.PubMedGoogle Scholar
  361. 361.
    Vigo DV, Baldessarini RJ. Anticonvulsants in the treatment of major depressive disorder: an overview. Harv Rev Psychiatry. 2009;17:231–41.PubMedGoogle Scholar
  362. 362.
    Viguera AC, Baldessarini RJ, Hegarty JM, Van Kammen D, Tohen M. Risk of discontinuing maintenance medication in schizophrenia. Arch Gen Psychiatry. 1997;54:49–55.PubMedGoogle Scholar
  363. 363.
    Viguera AC, Cohen LS, Baldessarini RJ, Nonacs R. Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can J Psychiatry. 2002;47:426–36.PubMedGoogle Scholar
  364. 364.
    Viguera AC, Cohen LS, Whitfield T, Reminick AM, Bromfield E, Baldessarini RJ. Perinatal use of anticonvulsants: differences in attitudes and recommendations among neurologists and psychiatrists. Arch Womens Ment Health. 2010;13:175–8.PubMedGoogle Scholar
  365. 365.
    Viguera AC, Newport DJ, Ritchie J, Stowe Z, Whitfield T, Mogielnicki J, et al. Lithium in breast milk and nursing infants: clinical implications. Am J Psychiatry. 2007;164:342–5.PubMedGoogle Scholar
  366. 366.
    Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RJ. Risk of discontinuing lithium maintenance in pregnant vs. nonpregnant women with Bipolar Disorders. Am J Psychiatry. 2000;157:179–84.PubMedGoogle Scholar
  367. 367.
    Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164:1817–24.PubMedGoogle Scholar
  368. 368.
    Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011;77:1156–64.PubMedGoogle Scholar
  369. 369.
    Yatham LN, Maj M, editors. Bipolar Disorder. Hoboken, NJ: Wiley-Blackwell; 2010.Google Scholar
  370. 370.
    Yeragani VK, Gershon S. Hammond and lithium: historical update. Biol Psychiatry. 1986;21:1101–2.PubMedGoogle Scholar
  371. 371.
    Yerby MS. Teratogenicity and antiepileptic drugs: potential mechanisms. Int Rev Neurobiol. 2008;83:181–204.PubMedGoogle Scholar
  372. 372.
    Yildiz A, Guleryuz S, Ankerst DP, Ongür D, Renshaw PF. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry. 2008;65:255–63.PubMedGoogle Scholar
  373. 373.
    Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology. 2011;36:375–89.PubMedGoogle Scholar
  374. 374.
    Yildiz A, Vieta E, Tohen M, Baldessarini RJ. Factors modifying drug and placebo responses in randomized trials for bipolar mania. Int J Neuropsychopharmacol. 2011;14:863–75.PubMedGoogle Scholar
  375. 375.
    Yonkers KA, Vigod S, Ross LE. Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstet Gynecol. 2011;117:961–77.PubMedGoogle Scholar
  376. 376.
    Wadzinski J, Franks R, Roane D, Bayard M. Valproate-associated hyperammonemic encephalopathy. J Am Board Fam Med. 2007;20:499–502.PubMedGoogle Scholar
  377. 377.
    Weissel M. [Administration of thyroid hormones in therapy of psychiatric illnesses (German)]. Acta Med Austriaca. 1999;26:129–31.PubMedGoogle Scholar
  378. 378.
    Wijeratne C, Draper B. Reformulation of current recommendations for target serum lithium concentration according to clinical indication, age and physical comorbidity. Aust N Z J Psychiatry. 2011;45:1026–32.PubMedGoogle Scholar
  379. 379.
    Williams RS, Cheng L, Mudge AW, Harwood AJ. Common mechanism of action for three mood-stabilizing drugs. Nature. 2002;417:292–5.PubMedGoogle Scholar
  380. 380.
    Wingo AP, Harvey PD, Baldessarini RJ. Effects of lithium on cognitive performance: meta-analysis. J Clin Psychiatry. 2009;70:1588–97.PubMedGoogle Scholar
  381. 381.
    Wilting I, Egberts AC, Movig KL, Laarhoven JH, Heerdink ER, Nolen WA. Association between concomitant use of serotonergic antidepressants and lithium-induced polyuria: multicenter medical chart review study. Pharmacopsychiatry. 2008;41:129–33.PubMedGoogle Scholar
  382. 382.
    Wong MM. Management of bipolar II disorder. Indian J Psychol Med. 2011;33:18–28.PubMedGoogle Scholar
  383. 383.
    World Health Organization (WHO). International Classification of Diseases and Related Health Problems, tenth revision (ICD-10). Geneva: World Health Organization; 1992.Google Scholar
  384. 384.
    Wyffels L, Muccioli GG, De Bruyne S, Moerman L, Sambre J, Lambert DM, et al. Synthesis, in vitro and in vivo evaluation, and radiolabeling of aryl anandamide analogues as candidate radioligands for in vivo imaging of fatty acid amide hydrolase in the brain. J Med Chem. 2009;52:4613–22.PubMedGoogle Scholar
  385. 385.
    Xu X, Müller-Taubenberger A, Adley KE, Pawolleck N, Lee VW, Wiedemann C, et al. Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid. Eukaryot Cell. 2007;6:899–906.PubMedGoogle Scholar
  386. 386.
    Zarate Jr C, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G. Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry. 2010;18:293–303.PubMedGoogle Scholar
  387. 387.
    Zarate CA, Manji HK. Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs. 2009;23:569–82.PubMedGoogle Scholar
  388. 388.
    Zarate Jr CA, Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA, et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord. 2007;9:561–70.PubMedGoogle Scholar
  389. 389.
    Zarin DA, Pass TM. Lithium and the single episode. When to begin long-term prophylaxis for bipolar disorder. Med Care. 1987;25(Suppl 12):S76–84.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Ross J. Baldessarini
    • 1
  1. 1.Harvard Medical SchoolMcLean Hospital Psychopharmacology ProgramBelmontUSA

Personalised recommendations